Silence Therapeutics plc (SLN) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $631M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSilence Therapeutics plc (SLN) trades at $13.36 with MoonshotScore 12/100 (Grade F). SLN is a biotechnology company focused on developing therapies for unmet medical needs. The company's pipeline includes treatments for rare diseases.
Price as of Sep 10, 2026 · Last analyzed: Sep 4, 2026SLN is a biotechnology company focused on developing therapies for unmet medical needs. The company's pipeline includes treatments for rare diseases.
Analyst Coverage for SLN: SLN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SLN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SLN: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Momentum (10/10, Strong). Weakest side: Growth Durability (0/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Silence Therapeutics plc Company Overview
Who Are SLN's Competitors?
SLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
| ZVRA Zevra Therapeutics, Inc. | $12.06 | +0.17% | $713M | — |
| PHAR Pharming Group N.V. | $10.97 | -4.61% | $776M | — |
| CLYM Climb Bio, Inc. | $14.54 | -3.42% | $832M | — |
| RIGL Rigel Pharmaceuticals, Inc. | $46.46 | -1.61% | $860M | — |
| TBPH Theravance Biopharma, Inc. | $17.02 | -0.23% | $882M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for SLN?
Financial-distress signal — its Altman Z-Score of -4.61 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 94% of our measures
- ● Price is current
- ● Latest filing 127 days ago
- ● No analyst coverage
Why 12?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.36 3-month price trend (Momentum)
- +0.31 12-month price trend (Momentum)
- +0.25 6-month price trend (Momentum)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.48 Revenue growth (Growth)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 58 |
| 2026-08-26 | 58 |
| 2026-08-29 | 58 |
| 2026-09-01 | 12 |
| 2026-09-04 | 12 |
| 2026-09-07 | 18 |
| 2026-09-10 | 12 |
What changed?
The grade moved from 58 to 12 (-46).
Over the same 18 days the stock moved +0.7%.
How Silence Therapeutics plc Is Valued
Silence Therapeutics plc carries a market capitalization of $631M, placing it in the small-cap category.
Silence Therapeutics plc Financial Trajectory
Silence Therapeutics plc (SLN) reported $421K in revenue for Q1 FY2026, reflecting 1139.1% growth compared to the prior quarter. The company recorded a net loss of $14.9M, with diluted EPS of $-0.96. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in its sector.
Key Financial Metrics
Return on assets is -56.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Silence Therapeutics plc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.61 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Silence Therapeutics plc has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 43.0% below estimates on average.
Insider Activity
Over the past six months, Silence Therapeutics plc insiders filed 17 SEC Form 4 transactions — 0 sales and 17 purchases. On net that is roughly 7.0M shares acquired (about $104.1M) — insiders putting money in tends to read as conviction.
SLN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2026 | $421,292 | -$15M | -$0.96 |
| Q4 FY2025 | $34,000 | -$12M | -$0.75 |
| Q3 FY2025 | $159,000 | -$21M | -$1.32 |
Q1 FY2026 · filed 7 May 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
SLN Latest News
-
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires · Sep 9, 2026
-
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
MT Newswires · Sep 8, 2026
-
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
benzinga · Sep 8, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Sep 4, 2026
SLN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SLN.
Price Targets
Wall Street price target analysis for SLN.
SLN MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. SLN scores 12/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Silence Therapeutics plc ADR Information Sponsored
Silence Therapeutics plc (SLN) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
Silence Therapeutics plc Stock: Key Questions Answered
What does the AI Score mean for SLN?
SLN holds an AI Score of 12/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is SLN a good stock?
Stock Expert AI does not rate SLN buy, sell or hold. Silence Therapeutics plc carries a MoonshotScore of 12/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for SLN?
Silence Therapeutics plc (SLN) holds an AI score of 12/100 (low). Not financial advice.
How frequently does SLN data refresh on this page?
SLN's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SLN's recent stock price performance?
Silence Therapeutics plc (SLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLN overvalued or undervalued right now?
Silence Therapeutics plc (SLN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SLN?
Yes, most major brokerages offer fractional shares of Silence Therapeutics plc (SLN) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SLN's earnings and financial reports?
Silence Therapeutics plc (SLN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SLN earnings announcements.
What should investors new to SLN understand first?
Silence Therapeutics plc (SLN) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 12/100. With a market cap of $631M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.